- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00253539
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells. Hormone therapy using arzoxifene or tamoxifen may prevent breast cancer by lowering the amount of estrogen the body makes. The use of arzoxifene or tamoxifen may keep breast cancer from forming in women at high risk for breast cancer.
PURPOSE: This randomized phase II trial is studying arzoxifene to see how well it works compared to tamoxifen or a placebo in preventing breast cancer in premenopausal women at high risk for breast cancer.
연구 개요
상세 설명
OBJECTIVES:
- Compare the effect of arzoxifene vs tamoxifen vs placebo on surrogate endpoints biomarkers, especially systemic insulin-like growth factor levels, in women at high risk for breast cancer.
- Compare the toxic effects, biologic effects, clinical pharmacology, and pharmacodynamics of these drugs in these participants.
- Determine the effect of these drugs on surrogate endpoint biomarkers in participants with BRCA1 and BRCA2 mutations.
- Determine the feasibility of a chemoprevention study in participants with a strong family history of breast cancer.
OUTLINE: This is a randomized, placebo-controlled, double-blind study. Participants are randomized to 1 of 3 treatment arms.
- Arm I: Participants receive oral tamoxifen once daily.
- Arm II: Participants receive oral arzoxifene once daily.
- Arm III: Participants receive an oral placebo once daily. In all arms, treatment continues for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment with their assigned study drug for an additional 6 months. Participants randomized to receive placebo are offered treatment with arzoxifene for an additional 6 months.
After completion of study treatment, participants are followed annually.
PROJECTED ACCRUAL: A total of 120 participants will be accrued for this study.
연구 유형
등록 (실제)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Estimated probability of carrying a BRCA1 or BRCA2 mutation ≥ 10% AND meets one of the following criteria:
Participants must have first-degree relatives (FDRs)* or second-degree relatives (SDRs)* (with an intervening male relative) with breast or ovarian cancer who satisfy one of the following criteria:
High-risk breast/ovarian cancer (non-Jewish families)
- One FDR ≤ 40 years old** diagnosed with breast cancer
- At least two FDRs or SDRs diagnosed with breast cancer at ≤ 50 years old OR had bilateral breast cancer
- One FDR or one SDR diagnosed with breast cancer at ≤ 50 years old OR had bilateral breast cancer AND one FDR or SDR diagnosed with ovarian cancer
- Three FDRs and/or SDRs diagnosed with breast or ovarian cancer (at least one in case of ovarian cancer)
- Two FDRs and/or SDRs diagnosed with ovarian cancer
- One male FDR or SDR diagnosed with breast cancer and one FDR or SDR (male or female) diagnosed with breast or ovarian cancer
Moderate-risk breast /ovarian cancer (non-Jewish families)
- Two FDRs diagnosed with breast cancer with one ≤ 50 years old and/or both < 60 years old
- One FDR and one SDR (mother or sister and maternal aunt or maternal grandmother) diagnosed with breast cancer if the sum of their ages is ≥ 118 years
- One FDR and one SDR (mother or sister and paternal aunt or paternal grandmother) diagnosed with breast cancer if the sum of their ages is ≥ 78 years
- Two SDRs (both maternal or both paternal) diagnosed with breast cancer if the sum of their ages is ≤ 98 years
- One FDR with ovarian cancer
High-risk breast/ovarian cancer (Jewish families )
- At least one FDR or SDR diagnosed with breast cancer at ≤ 50 years old
- At least one FDR or SDR diagnosed with ovarian cancer
- At least one FDR or SDR diagnosed with breast cancer at any age AND one FDR or SDR diagnosed with breast and/or ovarian cancer
- At least one male FDR or SDR diagnosed with breast cancer NOTE: *FDRs are parents, siblings, and children of the participant; SDRs are aunts, uncles, grandparents, grandchildren, nieces, nephews, or half siblings of the participant
NOTE: **Age is approximated to the earliest age possible (e.g., a relative diagnosed in their 40's should be considered 40)
- Patterns of cancer cases must all be on the maternal or paternal side of the family
Participants not meeting any of the above FDR or SDR criteria may provide medical documentation stating that they, a FDR, or a SDR carry BRCA1 or BRCA2 mutations
- Participants with a prior history of breast cancer are eligible provided they have a remaining breast that has not been irradiated, all therapy for breast cancer was completed more than 2 years ago, and they are premenopausal
- No ovarian cyst during screening
- No more than 12 months since prior Pap smear with normal cytological results OR human papilloma virus negative if atypical squamous cells of uncertain significance (ASCUS) present
No higher degrees of atypia beyond ASCUS on Pap smear
- No known history of osteoporosis (bone mineral density > 1.5 standard deviations below young adult norms)
- Hormone receptor status
- Not specified
PATIENT CHARACTERISTICS:
Menopausal status
Premenopausal, as defined by 1 of the following:
- Last menstrual period < 6 months ago
- Less than 45 years old AND underwent partial hysterectomy OR follicle-stimulating hormone within institutional pre-menopausal range within the past 3 months
Sex
- Female
Performance status
- ECOG 0-1
Life expectancy
- More than 2 years
Hematopoietic
- WBC ≥ 3,000/mm^3
- Platelet count ≥ 125,000/mm^3
- Hemoglobin ≥ 10 g/dL
Hepatic
- Bilirubin ≤ 1.5 mg/dL
- AST < 2 times upper limit of normal (ULN)
- Albumin ≥ 3.0 g/dL
- PT/PTT ≤ 1.25 times ULN
Renal
- Creatinine ≤ 1.5 mg/dL OR
- Creatinine clearance ≥ 60 mL/min
Cardiovascular
- No history of deep venous thrombosis
Pulmonary
- No history of pulmonary embolism
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile participants must use effective barrier-method contraception during and for 3 months after completion of study treatment
- No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or cervical cancer ≤ stage I
- No known addiction
- Not undergoing treatment for an illicit drug addiction
- Willing and able to undergo required study procedures (e.g., research-related breast biopsies)
PRIOR CONCURRENT THERAPY:
Chemotherapy
- More than 2 years since prior chemotherapy
Endocrine Therapy
- At least 3 months since prior oral contraceptives or intramuscular progestational agent
- At least 3 months since prior luteinizing-hormone releasing hormone (LHRH) agonists or antagonists if agent was administered daily or monthly
- At least 6 months since prior LHRH agonists or antagonists if agent was administered every 3 months
- At least 6 months since prior antiestrogens (e.g., tamoxifen, toremifene, and raloxifene)
- No concurrent progestational or contraceptive agents
Radiotherapy
- See Disease Characteristics
- More than 2 years since prior radiotherapy
Surgery
- No prior prophylactic bilateral mastectomy
Other
- No concurrent cholestyramine
- No concurrent routine warfarin, bromocriptine, or phenobarbital
- No other concurrent investigational agents
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Arm I
Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity.
After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
|
구두로 주어진
|
실험적: Arm II
Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity.
After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
|
Given orally
|
위약 비교기: Arm III
Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity.
After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
|
Given orally
구두로 주어진
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
---|---|
Ki67 in breast tissue of enrolled patients
|
The primary endpoint was changed in Ki67 in breast tissue of enrolled patients
|
2차 결과 측정
결과 측정 |
---|
독성
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CASE-CCF-4713
- P30CA043703 (미국 NIH 보조금/계약)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)모집하지 않고 적극적으로III기 전립선 선암종 AJCC v7 | II기 전립선 선암종 AJCC v7 | 1기 전립선 선암종 American Joint Committee on Cancer(AJCC) v7미국
타목시펜 구연산염에 대한 임상 시험
-
Limited Liability Company Pharm Aid완전한
-
Centre Hospitalier de BethuneCHU de Lille모병
-
NRG OncologyNational Cancer Institute (NCI)모병
-
Limited Liability Company Pharm Aid완전한로타바이러스 감염 | 로타바이러스 백신러시아 연방
-
Xiyuan Hospital of China Academy of Chinese Medical...Dongzhimen Hospital, Beijing; Beijing Hospital of Traditional Chinese Medicine; Beijing Obstetrics... 그리고 다른 협력자들알려지지 않은다낭성 난소 증후군 | 고프로락틴혈증 | 무배란성 불임 | 비정상적인 자궁 출혈-배란 장애 | 황체화 비파열 난포 증후군 | 황체 부전 | 난소 부전
-
Singapore General HospitalSengkang General Hospital모병
-
Children's Hospital of Chongqing Medical University완전한
-
American University of Beirut Medical Center모집하지 않고 적극적으로
-
Western Galilee Hospital-Nahariya완전한